Pharming announces extension of their license agreement for the commercialisation of Ruconest
Biotech company Pharming Group NV announced that they have agreed an extension of their existing agreement with Swedish Orphan Biovitrum to include new territories in the Balkans, North Africa and the Middle East for the commercialization of Ruconest® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with hereditary angioedema (HAE).
In addition, SOBI has placed a significant additional order for vials of Ruconest®. The shipment forms part of SOBI's preparation for the continued roll-out and intensified marketing of Ruconest® across Europe. SOBI will over a period of 1 year pay €1.5 million to Pharming for these additional shipments under this order. Under the terms of the distribution partnership, SOBI buys finished product from Pharming for a transfer price that includes a sales related tiered royalty component.
Sijmen de Vries, CEO of Pharming, said "We are delighted to expand our current commercialization deal with SOBI. This is another significant step towards making Ruconest more widely available. With this extension, patients in all EC territories, the Balkans, North Africa and the Middle East will soon be able to benefit from the efficacy and safety that Ruconest offers as the only recombinant enzyme replacement therapy for HAE".
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Caliper Life Sciences Launches Comprehensive Drug Discovery and Development Services Business
Prof Ian Frazer Appointed to Scientific Advisory Board of Avantogen's Hawaii Biotech, Inc.
Before retinal cells die, they regenerate, Penn vet blindness study finds
UF medicinal chemists modify sea bacteria byproduct for use as potential cancer drug
PharmaNeuroBoost’s lead product in major depression receives IND approval from FDA
WITec opens new regional headquarters in Singapore

A 'bio-refinery': using the chemistry of willow trees to treat municipal wastewater - Millions of litres of primary municipal wastewater can be treated sustainably using fast-growing willow trees while also producing renewable bioenergy and ‘green’ chemicals
Lymphoma overrides a key protein's quadruple locks
TxCell presents final positive results of the phase I/II clinical trial with antigen-specific Treg cells in Crohn’s disease
Two known chemotherapy agents effectively target breast cancer stem cells
Psilocybin eases existential anxiety in people with life-threatening cancer
